BACKGROUND: Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS: This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanoma patients prior to ICI therapy was analyzed by flow cytometry and complete blood count. RESULTS: Responders to ICI therapy displayed an abundance of proliferating CD4+ T cells, an increased lymphocyte-to-monocyte ratio, a low platelet-to-lymphocyte ratio, low levels of CTLA-4+ Treg, and (arginase 1+ ) polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). Nevertheless, non-responders with similar immune cell compositions also benefited from therapy displaying increased long-term OS. CONCLUSIONS: Our study demonstrated that the observed immune signature in the peripheral blood of melanoma patients prior to treatment could identify responders as well as non-responders that benefit from ICI immunotherapies.
BACKGROUND:Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS: This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanomapatients prior to ICI therapy was analyzed by flow cytometry and complete blood count. RESULTS: Responders to ICI therapy displayed an abundance of proliferating CD4+ T cells, an increased lymphocyte-to-monocyte ratio, a low platelet-to-lymphocyte ratio, low levels of CTLA-4+ Treg, and (arginase 1+ ) polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). Nevertheless, non-responders with similar immune cell compositions also benefited from therapy displaying increased long-term OS. CONCLUSIONS: Our study demonstrated that the observed immune signature in the peripheral blood of melanomapatients prior to treatment could identify responders as well as non-responders that benefit from ICI immunotherapies.
Authors: Ivelina Spassova; Selma Ugurel; Patrick Terheyden; Antje Sucker; Jessica C Hassel; Cathrin Ritter; Linda Kubat; Daniel Habermann; Farnoush Farahpour; Mohammadkarim Saeedghalati; Lukas Peiffer; Rajiv Kumar; David Schrama; Daniel Hoffmann; Dirk Schadendorf; Jürgen C Becker Journal: Clin Cancer Res Date: 2020-01-13 Impact factor: 12.531
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Omar S Qureshi; Yong Zheng; Kyoko Nakamura; Kesley Attridge; Claire Manzotti; Emily M Schmidt; Jennifer Baker; Louisa E Jeffery; Satdip Kaur; Zoe Briggs; Tie Z Hou; Clare E Futter; Graham Anderson; Lucy S K Walker; David M Sansom Journal: Science Date: 2011-04-07 Impact factor: 47.728
Authors: K H T Paraiso; I V Fedorenko; L P Cantini; A C Munko; M Hall; V K Sondak; J L Messina; K T Flaherty; K S M Smalley Journal: Br J Cancer Date: 2010-06-08 Impact factor: 7.640
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Souheil-Antoine Younes; George Punkosdy; Stephane Caucheteux; Tao Chen; Zvi Grossman; William E Paul Journal: PLoS Biol Date: 2011-10-11 Impact factor: 8.029
Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Julio C Valencia; Rebecca A Erwin-Cohen; Paul E Clavijo; Clint Allen; Michael E Sanford; Chi-Ping Day; Megan M Hess; Morgan Johnson; Jie Yin; John M Fenimore; Ian A Bettencourt; Koichi Tsuneyama; Maria E Romero; Kimberly D Klarmann; Peng Jiang; Heekyong R Bae; Daniel W McVicar; Glenn Merlino; Elijah F Edmondson; Niroshana Anandasabapathy; Howard A Young Journal: Cancer Res Date: 2021-10-12 Impact factor: 13.312
Authors: Jonathan Schupp; Arne Christians; Niklas Zimmer; Lukas Gleue; Helmut Jonuleit; Mark Helm; Andrea Tuettenberg Journal: Int J Mol Sci Date: 2021-01-20 Impact factor: 5.923
Authors: Niklas Zimmer; Emily R Trzeciak; Barbara Graefen; Kazuki Satoh; Andrea Tuettenberg Journal: Front Immunol Date: 2022-07-08 Impact factor: 8.786
Authors: Emily R Trzeciak; Niklas Zimmer; Isabelle Gehringer; Lara Stein; Barbara Graefen; Jonathan Schupp; Achim Stephan; Stephan Rietz; Michael Prantner; Andrea Tuettenberg Journal: Cells Date: 2022-03-08 Impact factor: 6.600